Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

What to do, when a Taltz® (ixekizumab) dose is missed?

The Taltz European Summary of Product Characteristics does not contain a specific recommendation about what to do when a patient forgets a dose of ixekizumab.

UK_cFAQ_IXE308_MISSED_DOSE_PsO_PEDS_PsA_axSpA
cFAQ
cFAQ
UK_cFAQ_IXE308_MISSED_DOSE_PsO_PEDS_PsA_axSpA
en-GB

Additional information on a missed dose

  • The US Taltz package insert states that if a dose is missed, the dose should be administered as soon as possible. Thereafter, resume dosing at the regular scheduled time.1
  • In the ixekizumab clinical development program, ixekizumab was administered at approximately the same time each day, as much as possible.2,3

Detailed Information from the Clinical Trials

The following information describes the procedure in the clinical trials with ixekizumab. The treatment decision remains at the discretion of the treating physician.

Plaque Psoriasis

  • For the pivotal UNCOVER adult psoriasis clinical trials, injections not administered on the scheduled day were to be administered
    • within 1 to 3 days of the scheduled day during the induction period (week 0-12), and
    • within 5 days of the scheduled day after week 12.2
  • For the IXORA-PEDS pediatric psoriasis clinical trial, injections not administered on the scheduled day were to be administered within 5 days of the originally scheduled day. Dates of subsequent study visits were not to be modified according to the delay.3

Psoriatic Arthritis

  • For the pivotal SPIRIT Psoriatic Arthritis clinical trials, injections not administered on the scheduled day were to be administered
    • within 3 to 4 days of the scheduled day from week 0 to week 24, and
    • within 4 to 5 days of the scheduled day after week 24.3

Radiographic axial Spondyloarthritis

  • For the pivotal COAST-V Ankylosing Spondylitis (AS)/ radiographic axial Spondyloarthritis (r-axSpA) clinical trial, injections not administered on the scheduled day were to be administered
    • within 3 days of the scheduled day from week 0 to week 16, and
    • within 5 days of the scheduled day after week 16.3
  • For the pivotal COAST-W AS/r-axSpA clinical trial, the missed injection was to be administered as soon as possible but not within 5 days of the next scheduled dose. Injections were to be at least 5 days apart and subsequent study visits were not to be modified according to this delay.3

Non-radiographic axial Spondyloarthritis

  • For the pivotal COAST-X non-radiographic axial Spondyloarthritis clinical trial, the missed injection was to be administered as soon as possible but not within 5 days of the next scheduled dose. Injections were to be at least 5 days apart and subsequent study visits were not to be modified according to this delay.3

References

1Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

3Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 15 April 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request